Entourage Health (ENTG) Q3 2024 earnings summary

Executive summary

• Achieved total revenue of CAD 13.6 million ($13.6 million) in Q3 2024, up 11% year-over-year, driven by strategic expansion, market diversification, and new product launches.

• EBITDA improved by 70% in the quarter and 65% year-over-year, reflecting cost management and operational efficiencies.

• SG&A expenses reduced by 32% year-over-year due to restructuring and cost-saving initiatives.

• Launched 23 new SKUs across core brands, with Dimebag contributing CAD 2.5 million in incremental revenue and 2,000 new retail placements.

• Focused on leading the medical cannabis market with innovative, patient-centric products and expanded insurance coverage.

Financial highlights

• Net revenue for Q3 2024 was CAD 9.5 million ($9.5 million), up 9% year-over-year; total revenue increased 11% year-over-year and 11.5% sequentially from Q2 2024.

• Gross profit before changes in fair value was CAD 2.9 million ($2.9 million), up 20% from Q3 2023; nine-month gross profit grew 24%.

• Gross profit margin improved to 30% from 27% in Q3 2023.

• SG&A expenses decreased by 32% year-over-year in Q3 and by 31% for the nine months ended September 30, 2024.

• Cash and cash equivalents at quarter-end were CAD 3.5 million ($3.6 million), down CAD 7.6 million from December 2023 due to operating losses.

Outlook and guidance

• Plans to launch new products and formats in 2025, including Chromatica, Sour Grapefruit Haze, Live Resin Infused Pre-rolls, and 25.5g mega packs.

• Focus remains on cash preservation, operational efficiency, and adapting to market conditions.

• Management is negotiating with its largest lender to resolve the current forbearance letter, which expires January 15, 2025.